<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body class="page">
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span><a href="/">&larr; Back to Home</a></span>
        <span class="date">2025-02-05</span>
        
        
        
          
        
        
        <span><a href="https://github.com/rainoffallingstar/daily-rss/edit/master/content/post/pubmed-ncbi-nlm-nih-gov-39910285-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20250206170927-v-2-18-0-post9-.md">Edit this page &rarr;</a></span>
        
        
      
      </div>
    </nav>

<div class="container">
<article>
<div class="article-meta">

  <div class="categories">
  
  </div>

  <h1><span class="title">Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma</span></h1>

  

  
  

</div>



<main>
<p>BCMA-targeted CAR T-cells transformed the treatment of relapsed and refractory multiple myeloma (RRMM), yet improvements are needed in manufacturing, toxicity and efficacy. We conducted a phase 1 clinical trial of BMS-986354, an autologous BCMA CAR T manufactured using an optimized NEX-T® process, in participants with triple-class exposed, RRMM. The 65 participants had a median of 5 (range 3-13) prior regimens, 39% had cytogenetic high-risk, 91% triple-class refractory, and 43% &hellip;</p>

<script>
var url = "https://pubmed.ncbi.nlm.nih.gov/39910285/?utm_source=curl\u0026utm_medium=rss\u0026utm_campaign=pubmed-2\u0026utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh\u0026fc=20220923065203\u0026ff=20250206170927\u0026v=2.18.0.post9+e462414";
var strReg = "http|https";
var re = new RegExp(strReg);
setTimeout(function() { if(re.test(url)) {window.location.href = url} }, 10000);
</script>
</main>




<nav class="post-nav">
  <span class="nav-prev"><a href="/post/pubmed-ncbi-nlm-nih-gov-39910281-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250206170938-v-2-18-0-post9-/">&larr; Validating candidate endpoints for intermediate age-related macular degeneration trials in a multi-centre setting-lessons from the MACUSTAR study</a></span>
  <span class="nav-next"><a href="/post/pubmed-ncbi-nlm-nih-gov-39910339-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20250206170938-v-2-18-0-post9-/">Real-world smartphone-based point-of-care diagnostics in primary health care to monitor HbA1c levels in people with diabetes &rarr;</a></span>
</nav>




</article>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

